ARO-MAPT Shows Deep CSF Tau Knockdown

Company Arrowhead Pharmaceuticals Event Type Interim Clinical Data (Phase 1/2a, healthy volunteers) Modality RNAi (siRNA); subcutaneous CNS delivery (TRiM platform) Asset ARO-MAPT Target MAPT (tau) Disease Area Alzheimer disease; tauopathies Summary Arrowhead reported interim Phase 1/2a data showing dose-dependent and durable cerebrospinal-fluid total-tau reductions after…